IFx-2.0

Gene therapy / editing

Phase 2/3underway

Evidence outlook · registrational

Merkel Cell Carcinoma: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2027-03-31.

Company guidance: data expected 1H2027 (TuHURA Biosciences, 13 Nov 2026). “1H2027: Expect preliminary results from front-line study IFX-2.0 with Keytruda® when administered by CT or ultrasound-guided techniques to metastatic deep seated MCC” Source ↗

Company guidance: topline data expected second half of 2027 (TuHURA Biosciences, 13 Nov 2026). “We anticipate topline results from the Phase 3 accelerated approval trial of IFx-2.0 in the second half of 2027.” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2/3 (1)
Merkel Cell Carcinoma
Phase 1 (4)
Merkel Cell Carcinoma
NCT06940440 · TuHURA Biosciences, Inc.
2026-01-27 – 2028-05-31 · Advanced Or Metastatic Merkel Cell Carcinoma
What this study did
NCT04160065 · TuHURA Biosciences, Inc.
2020-03-03 – 2024-08-13 · Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Non-Melanoma Skin Cancers
What this study did
Other / comorbidity
NCT04925713 · TuHURA Biosciences, Inc.
2021-06-10 – 2022-03-10 · Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma
What this study did
NCT03655756 · TuHURA Biosciences, Inc.
2018-11-05 – 2020-11-30 · Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV
What this study did

Competitive landscape

This drug's own stage for Merkel Cell Carcinoma: Phase 2/3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
IFx-2.0: this drugPhase 2/3Gene therapy / editingInnate immune activation (intralesional plasmid DNA)not yet gradedNo reviewed efficacy summary in this indication
AvelumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Weak signal
NCT03783078: Objective Response Rate (ORR) (Up to ~34 months): Pembrolizumab 200 mg 49.1 Percentage of participants (95% CI 35.4 to 62.9)
NCT02267603: Objective Response Rate (ORR) Defined as the Proportion of Patients Who Have Achieved Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (Up to 3 years): Treatment (Pembrolizumab) — Number participants with partial response (PR): 16 Participants; Number participants with complete response (CR): 12 Participants; Combined total participants with either PR or CR: 28 Participants
RetifanlimabApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow IFx-2.0 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
March 2027 (1)
Phase 2/3Merkel Cell CarcinomaRecruiting
Est. primary completion 2027-03-31 · NCT06947928 · CT.gov ↗
What to watch
April 2027 (1)
Phase 1Merkel Cell CarcinomaRecruiting
Est. primary completion 2027-04 · NCT06940440 · CT.gov ↗
What to watch

See the full readout calendar ↗